We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

36 hedge funds and large institutions have $1.5M invested in Oncolytics Biotech in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.45% less ownership

Funds ownership: 7.33% → 1.87% (-5.5%)

18% less funds holding

Funds holding: 44 → 36 (-8)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

79% less capital invested

Capital invested by funds: $7.26M → $1.5M (-$5.76M)

Holders
36
Holders Change
-8
Holders Change %
-18.18%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
9
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$93.4K
2
VF
Virtu Financial
New York
+$58K
3
Citadel Advisors
Citadel Advisors
Florida
+$54.6K
4
PI
PFG Investments
New York
+$11.7K
5
AI
Atom Investors
Texas
+$11.5K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$5.15M
2
ARC
Advisor Resource Council
Texas
-$135K
3
Morgan Stanley
Morgan Stanley
New York
-$128K
4
Millennium Management
Millennium Management
New York
-$97.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$40.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Atom Investors
Texas
$10.9K +$11.5K +10,257 New
CMA
27
Cedar Mountain Advisors
Oregon
$5.99K – – –
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.68K – – –
Wells Fargo
29
Wells Fargo
California
$4.67K -$294 -263 -6%
IA
30
IFP Advisors
Florida
$2.65K +$2.79K +2,500 New
Carson Wealth (CWM LLC)
31
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
UBS Group
32
UBS Group
Switzerland
$1.23K -$3.95K -3,535 -75%
JFA
33
JNBA Financial Advisors
Minnesota
$223 – – –
CQS
34
Credential Qtrade Securities
$55 +$58 +52 New
WWM
35
Wolff Wiese Magana
California
$33 – – –
1832 Asset Management
36
1832 Asset Management
Ontario, Canada
$5 – – –
AFM
37
Anson Funds Management
Texas
– -$5.15M -3,814,299 Closed
ARC
38
Advisor Resource Council
Texas
– -$135K -100,000 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$40.9K -30,306 Closed
NDSI
40
Newman Dignan & Sheerar Inc
Rhode Island
– -$29.7K -22,015 Closed
SC
41
Scotia Capital
Ontario, Canada
– -$14.1K -10,679 Closed
Bank of America
42
Bank of America
North Carolina
– -$8.24K -6,101 Closed
Toronto Dominion Bank
43
Toronto Dominion Bank
Ontario, Canada
– -$4.8K -3,554 Closed
Barclays
44
Barclays
United Kingdom
– -$1.62K -1,200 Closed
TWC
45
TD Waterhouse Canada
Ontario, Canada
– -$970 -557 Closed
PCMC
46
Planning Capital Management Corporation
Pennsylvania
– -$291 -215 Closed
ASN
47
Advisory Services Network
Georgia
– -$135 -100 Closed
CCMW
48
Cypress Capital Management (Wyoming)
Wyoming
– -$135 -100 Closed
HPC
49
HM Payson & Co
Maine
– -$38 -28 Closed
TRCT
50
Tower Research Capital (TRC)
New York
– -$23 -17 Closed
1
2

ONCY Hedge Fund Activity: Q1 2024 in Review

36 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2024, worth a combined $1.5M — down 79% from $7.26M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ONCY and 7 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 7 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $93.4K. The largest seller was Anson Funds Management, exiting entirely with an estimated $5.15M sold.

  • 36 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2024, down from 44 in Q4 2023.
  • Funds reported $1.5M of Oncolytics Biotech stock for Q1 2024, down 79% quarter-over-quarter.
  • 7 funds opened new Oncolytics Biotech positions in Q1 2024 and 14 closed out, a net change of -7 holders.
  • The largest Oncolytics Biotech buyer in Q1 2024 was Goldman Sachs, an estimated $93.4K added.
  • The largest Oncolytics Biotech seller in Q1 2024 was Anson Funds Management, an estimated $5.15M sold.

Based on aggregated 13F filings for Q1 2024.